We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+19.19%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$783M
AUM Growth
+$36.9M
Cap. Flow
-$49.7M
Cap. Flow %
-6.35%
Top 10 Hldgs %
34.67%
Holding
106
New
16
Increased
38
Reduced
39
Closed
13

Top Buys

Rank Stock Value
1
TFX icon
Teleflex
TFX
+$22.4M
2
KROS icon
Keros Therapeutics
KROS
+$11M
3
SYK icon
Stryker
SYK
+$9.66M
4
RCUS icon
Arcus Biosciences
RCUS
+$9.62M
5
DGX icon
Quest Diagnostics
DGX
+$8.21M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$16M
2
ELV icon
Elevance Health
ELV
+$15M
3
HUM icon
Humana
HUM
+$11.2M
4
COR icon
Cencora
COR
+$8.56M
5
THC icon
Tenet Healthcare
THC
+$8.34M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OSCR icon
51
Oscar Health
OSCR
$9.14B
$5.3M 0.68%
+250,000
New +$4.5M
MLTX icon
52
MoonLake Immunotherapeutics
MLTX
$1.47B
$5.18M 0.66%
102,813
+1,589
+2% +$74.5K
TEVA icon
53
Teva Pharmaceuticals
TEVA
$42.8B
$5.14M 0.66%
285,294
-68,648
-19% -$1.2M
DXCM icon
54
DexCom
DXCM
$34.3B
$4.73M 0.6%
70,588
-86,267
-55% -$7.08M
ANAB icon
55
AnaptysBio
ANAB
$1.69B
$4.63M 0.59%
138,100
-118,207
-46% -$4.04M
TERN
56
DELISTED
Terns Pharmaceuticals
TERN
$4.55M 0.58%
545,751
+155,481
+40% +$1.28M
URGN icon
57
UroGen Pharma
URGN
$2.39B
$4.41M 0.56%
347,541
+73,076
+27% +$1.08M
VCYT icon
58
Veracyte
VCYT
$3.59B
$4.4M 0.56%
129,260
-80,215
-38% -$2.26M
CRNX icon
59
Crinetics Pharmaceuticals
CRNX
$8.96B
$3.97M 0.51%
77,623
-63,752
-45% -$3.29M
BCRX icon
60
BioCryst Pharmaceuticals
BCRX
$2.71B
$3.53M 0.45%
464,048
+63,600
+16% +$483K
QDEL icon
61
QuidelOrtho
QDEL
$1.02B
$3.42M 0.44%
+75,000
New +$3.03M
AVDL
62
DELISTED
Avadel Pharmaceuticals
AVDL
$3.34M 0.43%
254,827
-123,462
-33% -$1.88M
LENZ
63
LENZ Therapeutics
LENZ
$158M
$3.31M 0.42%
+139,357
New +$3.09M
THRD
64
DELISTED
Third Harmonic Bio
THRD
$3.22M 0.41%
237,820
+104,495
+78% +$1.29M
LFST icon
65
Lifestance Health
LFST
$4.67B
$3.15M 0.4%
+450,000
New +$2.7M
TGTX icon
66
TG Therapeutics
TGTX
$7.58B
$2.96M 0.38%
126,471
-53,849
-30% -$1.18M
SIBN icon
67
SI-BONE Inc
SIBN
$852M
$2.59M 0.33%
185,316
+32,301
+21% +$486K
INSM icon
68
Insmed
INSM
$28.9B
$2.59M 0.33%
35,433
-44,838
-56% -$3.31M
DVAX
69
DELISTED
Dynavax Technologies
DVAX
$2.44M 0.31%
219,451
+2,629
+1% +$29K
NUVL
70
DELISTED
Nuvalent
NUVL
$2.39M 0.31%
23,400
-19,488
-45% -$1.62M
ARVN icon
71
Arvinas
ARVN
$580M
$2.37M 0.3%
96,183
-28,978
-23% -$757K
MRUS
72
DELISTED
Merus
MRUS
$2.27M 0.29%
45,349
+197
+0.4% +$10.3K
ATEC icon
73
Alphatec Holdings
ATEC
$1.49B
$2.2M 0.28%
396,336
-456,080
-54% -$3.5M
EPIX
74
DELISTED
ESSA Pharma
EPIX
$2.1M 0.27%
345,902
+93,830
+37% +$515K
ANNX icon
75
Annexon
ANNX
$873M
$1.95M 0.25%
328,613
+1,768
+0.5% +$10.5K
1 2
3
4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q3 2024 Portfolio in Review

As of Q3 2024, Parkman Healthcare Partners held 106 positions worth $783M, up 4.9% from $747M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Parkman Healthcare Partners withdrew a net $49.7M in Q3 2024, closing 13 positions and reducing 39 holdings. Its most notable exit was Elevance Health, an estimated $15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Industrials.

Against the trend, Parkman Healthcare Partners opened a new position in Teleflex worth $23.8M.

  • Parkman Healthcare Partners's largest Q3 2024 buy was Teleflex: 96,144 shares worth $23.8M.
  • Parkman Healthcare Partners added most to Keros Therapeutics in Q3 2024, an estimated $11M increase.
  • Parkman Healthcare Partners's biggest Q3 2024 reduction was United Therapeutics, cutting an estimated $16M.
  • Parkman Healthcare Partners fully exited Elevance Health in Q3 2024, selling an estimated $15M.
  • Parkman Healthcare Partners's ten largest holdings make up 35% of its $783M portfolio in Q3 2024.
  • Parkman Healthcare Partners opened 16 new positions and closed 13 in Q3 2024.
  • Parkman Healthcare Partners's portfolio value rose 4.9% quarter-over-quarter to $783M.

Based on Parkman Healthcare Partners's 13F filing for Q3 2024, filed 14 Nov 2024.